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Abstract  13 
 The aim of this observational cohort study was to investigate the potential economic 14 
effect of sub-clinical Bovine Herpes Virus 1 (BoHV-1) infection in a commercial UK dairy 15 
herd in terms of milk yield depression.  Infection status of cows (infected or not infected) was 16 
assigned from serology on a single occasion.  A multi-level linear model was used to evaluate 17 
the effect of infection status on milk production, using milk records that were routinely 18 
collected over two years.  BoHV-1 seropositive cows produced 2.6 kg/day less milk over the 19 
study period compared with cows that were seronegative.  This result highlights the 20 
importance of appropriate management of risks associated with BoHV-1 as part of proactive 21 
herd health and production management.  22 
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Introduction 26 
Losses from infectious diseases of livestock are most easily comprehended if 27 
associated with clinical signs.  For example, incursion of Bovine Herpesvirus 1 (BoHV-1) 28 
into a naïve population of adult dairy cows typically leads to a variety of clinical syndromes 29 
described as Infectious Bovine Rhinotracheitis (IBR).  These may include respiratory, ocular 30 
and nervous signs, accompanied by pyrexia, infertility and abortions and associated sudden 31 
decrease in milk yield (Nettleton 2007).  However, both in previously exposed groups with 32 
recrudescence of virus from latently infected cattle, or in new infections of naïve animals, 33 
BoHV-1 may instead lead to sub-clinical disease and insidious production losses, rather than 34 
overt clinical signs (van Schaik and others 1999).  Despite an effective systemic immune 35 
response, BoHV-1 can persist in sensory nervous ganglia of infected cattle contributing to 36 
endemic herd infection (Ackermann and Engels 2006).  The intractable nature of BoHV-1 37 
contributes to potentially serious economic consequences and an adverse impact on animal 38 
welfare.  Trade restrictions are a significant driver of decisions to implement co-ordinated 39 
control at a national level.  This has encouraged the Governments of six European countries 40 
to make IBR a notifiable disease, legislate to cull infected cattle from herds, and become 41 
‘IBR-free’ (Ackermann and Engels 2006).  Elsewhere, the management of BoHV-1 infection 42 
has been generally less regulated, although compulsory regional eradication schemes are in 43 
place, for example in the Italian province of Trento, with European Commission approval and 44 
voluntary health schemes are available to support and certify eradication at herd level 45 
(Statham 2011).   46 
In England and Wales, the prevalence of dairy herds endemically infected with 47 
BoHV-1 has seemingly increased in recent decades based on the presence of specific 48 
antibody in bulk milk  (Paton and others 1998; Williams and Winden 2014) and completely 49 
naïve UK dairy herds are probably uncommon in cattle dense regions (Woodbine and others 50 
2009).  51 
 Estimates of the direct costs of IBR to the UK farming industry have been put at up to 52 
£4 million per annum (Bennett 2003).  Data on milk production impacts of BoHV-1 are 53 
described by van Schaik and others (1999) in herds that experienced clinical IBR outbreaks.  54 
However, milk production losses from sub-clinical disease in commercial dairy cows have 55 
not been demonstrated. Bosch and others (1996, 1997) described the dynamics of BoHV-1 56 
infection in experimental challenge studies on 30 yearling animals, but a major challenge 57 
remains in assessing the relative economic importance of sub-clinical versus clinical impacts 58 
associated with BoHV-1 infection  in commercial dairy herds.  Understanding whether the 59 
losses are due to incursion of a new infection with BoHV-1 compared with reactivation of 60 
existing latent infection is also important in understanding the relative importance of 61 
biosecurity in control of IBR.  Hage and others (1998) estimated a reduced milk yield of 9.5 62 
litres per animal at the time of seroconversion in the Netherlands.  However, Hage (1998) 63 
measured production effects over only five weeks and van Schaik and others (1999) over nine 64 
weeks.  The effects of sub-clinical BoHV-1 infection on milk production over a longer period 65 
have not been studied.  66 
The aim of this study was therefore to investigate the potential effect of subclinical 67 
BoHV-1 infection on milk production over a two year period in a commercial UK dairy herd. 68 
 69 
Materials and methods  70 
Study herd background 71 
The data refer to an autumn-calving dairy herd of 129 pedigree Holstein cows with 72 
approximate annual milk yield of 9,000 kg per cow.  The main farm was in a low cattle 73 
density region of Northern England, with land double fenced or bordered by open moorland.  74 
No cattle had been moved onto the farm from another holding since before 2000 and 75 
replacements were homebred by artificial insemination with no use of stock bulls.  Heifers 76 
were sometimes grazed away from the main farm at the periphery of the holding.  Protective 77 
clothing was provided for essential visitors.  Based on annual or biannual bulk milk serology 78 
and intermittent blood samples from young stock, the herd was assumed uninfected with 79 
BoHV-1. In 2009, the conventional milking parlour was replaced with two robotic milking 80 
machines.  At the same time, the diet was adjusted to include higher proportions of 81 
concentrate feed and milk yields increased.  Serological testing of bulk milk was deemed 82 
‘negative’ up to and including February 2010 but was seropositive by May 2010 (Table 1). 83 
 84 
Apparent incursion of BoHV-1 85 
Three adult cows aborted in May 2010; one developed respiratory signs and died.  86 
Investigation using serology for BoHV-1 antibody via blocking glycoprotein ‘B’ (gB) 87 
Enzyme- Linked Immunosorbent Assay (ELISA) (de Wit and others 1998) was performed 88 
and these cows were found to be seropositive.  Antibodies to BoHV-1 were also identified in 89 
bulk milk in May 2010 and the herd was classified seropositive.  No other clinical signs 90 
associated with BoHV-1 were detected throughout the herd; the remaining cows appeared 91 
healthy, and were individually blood sampled for BoHV-1 antibody via blocking 92 
glycoprotein ‘B’ (gB) Enzyme- Linked Immunosorbent Assay (ELISA) (de Wit and others 93 
1998).  Cows were classified as ‘BoHV-1 seropositive’ and ‘BoHV-1 seronegative’ using a 94 
threshold optical density > 0.25 as seropositive (Pritchard and others 2003).  Seventy two per 95 
cent of cows were seropositive to BoHV-1 on individual sampling in May 2010 based on a 96 
commercial competitive ELISA (IDEXX IBR gB ELISA, Animal and Plant Health Agency 97 
(APHA); Table 2).  98 
Ten animals from the seronegative group blood sampled in May 2010 were selected 99 
on convenience and resampled using the IDEXX IBR gE blocking ELISA (APHA) in August 100 
2010 for the presence of antibodies against BoHV-1 glycoprotein ‘E’ (gE)). 101 
 102 
Data analysis 103 
Data from monthly cow level test day milk records (National Milk Records, 104 
Chippenham, UK) between January 2009 and December 2010 were collected.  Records of 105 
milk, fat and protein production along with somatic cell count (SCC) for each test day were 106 
collated alongside BoHV-1 antibody status for each cow.  A multi-level linear model was 107 
used for analysis, and this took the form; 108 
yij = α + Xijβ1 + Xj β2 + uj + eij 109 
uj ~ Normal (0, σ
2
u) 110 
eij ~ Normal (0, σ
2
e) 111 
where yij = milk yield at test day i, for cow j, α = intercept value, Xij = matrix of exposure 112 
variables for each test day, β1 = vector of coefficients for Xij, Xj = matrix of exposure 113 
variables for each cow, β2 = vector of coefficients for Xj, uj = a random effect to account for 114 
residual variation between cows (assumed to be normally distributed with mean = 0 and 115 
variance = σ2u), and eij = residual level 1 error (assumed to be normally distributed with 116 
mean = 0 and variance = σ2e).  Model parameters were estimated by the iterative generalized 117 
least squares procedure (Goldstein 2003), using MLwiN 2.22 (Rasbash and others 2009).  118 
Categorical variables were constructed for calendar month (1 = January, 2 = February, 119 
3 = March, 4 = April, 5 = May, 6 = June, 7 = July, 8 = August, 9 = September, 10 = October, 120 
11 = November, 12 = December), and parity (1, 2, 3, ≥ 4).  The category with the smallest 121 
impact on test day milk yield was used as the baseline.  Lactation curve shape was included 122 
as number of days in milk (DIM) + e
(-0.065 X DIM)
 (Silvestre and others 2006; Archer and others 123 
2013), and these variables were centred on 5 DIM.  To adjust test day milk yield according to 124 
its composition, percentage of fat and protein were included, centred on their means.  SCC 125 
was investigated on linear and log linear scales (Green and others 2006), centred on mean 126 
values. Biologically plausible interactions were assessed.  Variables were retained from the 127 
saturated model where P ≤ 0.05 and their inclusion resulted in a decrease in the deviance.  128 
Model fit was assessed by graphical inspection of residuals. 129 
 130 
Results 131 
Seventy two per cent of cows were seropositive to BoHV-1 on individual blood 132 
samples taken in May 2010.  Risk of seroconversion varied with parity (Table 2 and 3). The 133 
129 cows had 2,121 test day records over the two year study period.  Means (standard 134 
deviation) of test day milk yield, DIM, and parity were 34 (10) kg, 174 (105) days, and 2.7 135 
(1.7), respectively.  Importantly, cows that were seropositive to BoHV-1 in May 2010 136 
produced 2.6 (95% CI 2.0 to 3.2; p =< 0.05) kg/day less milk throughout lactation compared 137 
to those that were seronegative (Table 3; Figure 1).  Confounding factors influencing test day 138 
milk yield were calendar month, parity, stage of lactation, test day fat and protein percentage, 139 
and SCC (Table 3).  Residuals from the model were distributed normally indicating a good fit 140 
to the data.  Ten animals that were seronegative for the presence of gE antigen to BoHV-1 in 141 
May 2010 remained seronegative three months later in August 2010. 142 
 143 
Discussion 144 
 This study has identified a large decrease in the potential daily milk yield of cows 145 
associated with subclinical infection with BoHV-1.  Compared to seronegative cows, those 146 
cows with antibodies to BoHV-1 on average failed to produce almost 1,000 kg of milk per 147 
year.  In the herd studied this could relate to lost income of £200/ cow
1
 having accounted for 148 
the reduction in feed costs assuming feed conversion efficiency is unchanged 149 
(margin = £0.2 / kg) (Kingshay Farming, personal communication).  The mean estimate of 150 
potential milk loss in this study is larger and predicted to last longer than previous estimates 151 
which have varied from nil (Pritchard and others 2003) in an English herd in East Anglia, 152 
to 10 kg per cow over 2 weeks (Hage and others 1998), or around 1 kg per cow per day over 153 
9 weeks (van Schaik and others 1999) in Dutch dairy herds.  This variation could relate to 154 
differences in disease dynamics between cows in different herds, between studies, BoHV-1 155 
strain or in the analytical methods used.  156 
Infection status of cows is assumed based on a single individual sampling for serology 157 
in this herd.  We therefore infer nothing about the temporal dynamics of virus circulation in 158 
the herd, other than the observed change in herd classification based on bulk milk serology.  159 
This approach to identifying a change in herd infection status based on bulk milk sampling 160 
has been previously described (van Schaik and others 1999).  Once cows are infected with 161 
BoHV-1 the infection is long standing, and they remain antibody positive indefinitely 162 
(Nettleton 2007).  Therefore, the most likely error in our classifications is that some negative 163 
cows seroconverted following sampling.  If this occurred we may have underestimated the 164 
mean association of BoHV-1 infection with daily milk yield.  Repeat sampling of cows from 165 
the seronegative cohort failed to show evidence of seroconversion between May and August 166 
2010. No published test characteristics are available for the ELISA test assay used.  However, 167 
Kramps and others (1994) estimated the sensitivity of an analogous non-commercial test to 168 
be 0.99.  169 
The outbreak may have occurred through a new incursion of BoHV-1 virus or 170 
reactivation of unidentified latent infection.  It is not possible to definitively identify the 171 
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 £1 = approx. US$1.64, €1.21 at 17 January 2014: http://uk.reuters.com/business/currencies  
source of infection in this case but on balance a new incursion seems more likely, as there 172 
was no evidence of infection before 2010.  We believe BoHV-1 may have been introduced to 173 
the herd through introduction of heifers.  These were sometimes managed on separate more 174 
peripheral grazing at the boundary of the farm holding prior to calving.  A biosecurity breach 175 
in this group would be consistent with the observed high prevalence of seropositive cows in 176 
parity 1 (Table 1).  Parity ≥4 cows have been in the herd longer and are therefore more likely 177 
to have been exposed to BHV-1 and developed immunity; they may be infected but not 178 
infectious.  These are two potentially vulnerable groups in this herd, with social stress factors 179 
for parity 1 animals entering the herd but higher yield and energy deficit for parity ≥4 cows; 180 
both potentially compromising immune function (Wathes and others 2007; Friggens and 181 
others 2013). 182 
BoHV-1 is an increasingly important cattle pathogen (Woodbine and others 2009).  183 
The challenge in commercial dairy herds is often to develop strategies to manage higher 184 
yielding cows to optimise health and productivity and selecting for robust cows with 185 
characteristics that are suited to the particular system (Friggens and others 2013).  As milk 186 
yields increase, even ‘closed’ dairy herds typically require more inputs through deliveries and 187 
visitors which could compromise bio-security and increase infectious disease risks.  Herd 188 
health and production management (HHPM) includes prioritisation of management 189 
interventions (Green 2012).  Sub-clinical disease may be inapparent without an effective 190 
monitoring strategy.  The large potential loss in milk production in this study associated with 191 
sub-clinical disease highlights the importance of effective risk management such as through 192 
biosecurity and vaccination in infectious disease control. 193 
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Table 1.  Summary of bulk milk Bovine Herpes Virus 1 (BoHV-1) serology results.  1 
 
                           BoHV-1 status 
 
Bulk milk antibodies 
to BoHV-1 sampling 
date (Laboratory) 
Cow management 
group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Bulk milk Optical Density 
(OD) result
Reference 
range 
04.08.2005 (APHA
1
) 
16.02.2010 (SAC
2
) 
Pooled milking herd 
 
Pooled milking herd 
0.071 negative 
 
1% seropositive 
(Negative 
<0.10) 
(negative <3%; 
positive>5%) 
10.5.2010 (SAC
2
) Pooled milking herd 45% positive  (negative <3%; 
positive>5%) 
17.5.2010 (APHA
1
) Parlour group 0.94 High positive (High 
positive>0.7;  
>60% 
seropositive) 
 
17.5.2010 (APHA
1
) Robot group 0.22 Low positive  (Low positive 
0.10-0.40;  
<20% 
seropositive) 
1
Animal and Plant Health Agency (IDEXX IBR Pool Milk ELISA; negative <0.10; low positive 0.10-0.40; high positive>0.7) 1 
2
Scottish Agricultural College (Svanovir® IBR Ab ELISA, indirect; negative <3%; positive>5%)2 
Table 2.  Counts and proportions of cows identified with Bovine Herpes Virus 1 infection
1
 by 1 
parity in May 2010. 2 
 
BoHV-1 status 
 
Parity Negative Positive 
Proportion 
positive 
1 5 24 0.83 
2 16 20 0.56 
3 11 14 0.56 
≥4 5 34 0.87 
1
Based on identification of antibodies in serum (optical density > 0.25).  3 
Table 3.  Final multi-level linear model for test day milk yield (kg/day) within cow 1 
Fixed effects (baseline) 
 
Mean effect 
95% Confidence 
interval
1
 
Intercept 
 
25.8 18.8 32.8 
BoHV
2
 (BoHV = 0) 
 
-2.6 -3.2 -2.0 
Parity (1) 2 6.4 0.8 12.0 
 
3 6.2 0.0 12.4 
 
≥4 8.9 3.7 14.1 
DIM
3
 (5) 
 
-0.02 -0.02 -0.02 
e
( -0.065 x DIM) 
(DIM = 5) 
 
-9.5 -20.7 1.7 
DIM & Parity  2 -0.03 -0.03 -0.03 
 
3 -0.05 -0.05 -0.05 
 
≥4 -0.05 -0.05 -0.05 
e
( -0.065 x DIM) 
& Parity 2 -11.8 -20.4 -3.2 
 
3 -22.0 -31.6 -12.4 
 
≥4 -18.8 -26.8 -10.8 
Calendar Month 
(December) January 4.8 -2.4 12.0 
 
February 8.2 1.4 15.0 
 
March 8.6 -1.0 18.2 
 
April -5.7 -15.5 4.1 
 
May 3.8 -4.4 12.0 
 
June 10.5 -2.3 23.3 
 
July 2.8 -11.8 17.4 
 August 6.6 -4.4 12 
 
September 3.1 -6.3 12.5 
 
October 2.3 -6.1 10.7 
 
November 5.7 -6.9 18.3 
DIM & Calendar month January 0.02 0.02 0.02 
 
February 0.02 0.02 0.02 
 
March 0.00 0.00 0.00 
 
April -0.00 -0.00 -0.00 
 
May 0.01 0.01 0.01 
 
June -0.00 -0.00 -0.00 
 
July -0.02 -0.02 -0.02 
 
August -0.00 -0.00 -0.00 
 
September -0.01 -0.01 -0.01 
 
October 0.00 0.00 0.00 
 
November 0.00 0.00 0.00 
e
( -0.065 x DIM) 
& Calendar 
month January 17.0 5.2 28.8 
 
February 20.0 8.8 31.2 
 
March 16.3 1.1 31.5 
 
April -5.8 -21 9.4 
 
May 10.2 -3.2 23.6 
 
June 15.9 -3.7 35.5 
 
July 0.10 -0.1 0.3 
 
August 8.5 -8.5 25.5 
 
September 0.5 -14.7 15.7 
 October 4.3 -9.7 18.3 
 
November 10.0 -10 30 
SCC (‘000/mL) (mean) 
 
-0.00 0.00 0.00 
Fat % (mean) 
 
-2.1 -2.5 -1.7 
Protein % (mean) 
 
-6.4 -7.6 -5.2 
Random effects 
 
Variance   
Cow level 
 
22.8 18.8 26.8 
Recording level 
 
17.9 14.5 21.3 
1 
The 95% confidence interval includes values where P ≤ 0.05. This is significant if the interval excludes 0 1 
2 
Seroconversion to Bovine Herpes Virus 1 (binary exposure) 2 
3 
Days in milk  3 
 4 
  5 
Figure 1. Mean predicted lactation curve shape by BoHV-1antibody status. Refers to parity 1 1 
cows in December with mean milk fat, protein and somatic cell count. 2 
 3 
